Legal entity
Every one of those 1 sits in a single category, regulation. Of the tracked stories, 1 of 1 also mention Alcon, the most common co-covered peer. Each story carries 5 original sources on average, compared with 3.4 for the broader beat in this window.
Last mentioned: Mar 18, 2026
Entity pulse
Coverage balance Negative coverage leads. Negative coverage exceeds positive coverage by 100 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Every one of those 1 sits in a single category, regulation. Of the tracked stories, 1 of 1 also mention Alcon, the most common co-covered peer. Each story carries 5 original sources on average, compared with 3.4 for the broader beat in this window. At 6, the average consequence score sits below the same-window beat average of 6.2. LENSAR appears in 1 tracked Legal story from March 17, 2026.
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 54 Legal stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering LENSAR. Shared-story counts are live from our verified record — not editorial picks.
Alcon has terminated its planned acquisition of LENSAR following opposition from the Federal Trade Commission, highlighting intensified antitrust enforcement in the medical technology sector. Simultaneously, labor unrest at JBS USA and mixed earnings from Getty Images underscore broader economic pressures as global markets trend downward.
LENSAR is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
